Although idiopathic pulmonary fibrosis (IPF) is considered a rare disease, its burden is high.5
In a study of American Medicare beneficiaries, patients with IPF had a higher risk of hospitalisation (28.8 vs. 15.8%) and emergency room visits (23.9 vs. 13.1%) compared to matched control subjects.6
Total medical costs of IPF were found to be around 31,000 USD/person-year, including treatment before and after diagnosis.6
Patients’ and their families’ quality of life are greatly affected by:7
Patients report substantial impairment on their health-related quality of life (HRQoL), especially in domains that measure physical health, activity and level of independence.8,9
Dyspnoea, cough and severity of depression particularly affect quality of life in patients with IPF, with dyspnoea the most significant contributor.8
Longitudinal data show that forced vital capacity decline is also associated with worsening HRQoL in patients.8
Despite the effect of IPF on patient quality of life, Professor Elisabeth Bendstrup recalls one of her patients who was determined to achieve his goal and managed it with the help of anti-fibrotic treatment. Find out more.